Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene

Macquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressures and geopolitical factors, prompting a global restructuring of the pharmaceutical supply chain.